BioCentury | Apr 4, 2020
Product Development

More muddled results from the amyloid hypothesis with DIAN-TU readout

...changes in dosing. The Phase II/III trial, which evaluated gantenerumab from Roche (SIX:ROG; OTCQX:RHHBY) and solanezumab...
...at study completion were a 27 to 12 split between presymptomatic and symptomatic; the 36 solanezumab...
...symptoms. Its primary completion date is listed as July 2022 in clinicaltrials.gov. Selina Koch, Executive Editor solanezumab (LY2062430) gantenerumab...
BioCentury | Feb 11, 2020
Product Development

Alzheimer’s prevention replays the same amyloid failures as the treatment setting

...The Phase II/III DIAN-TU trial of Lilly’s solanezumab and Roche’s gantenerumab was always a long shot...
...Monday, Eli Lilly and Co. (NYSE:LLY) and Roche (SIX:ROG; OTCQX:RHHBY) announced that the anti-amyloid therapies solanezumab...
...enzyme 1 PSEN1 (PS1) - Presenilin 1 PSEN2 (PS2) - Presenilin 2 Lauren Martz, Senior Editor solanezumab (LY2062430) gantenerumab...
BioCentury | Jan 30, 2020
Company News

Lilly culls most of its clinical immuno-oncology pipeline

...for data expected this quarter from the Phase III A4 trial of anti-β amyloid mAb solanezumab...
...T cell immunoglobulin and mucin domain 3 Consensus estimates provided by FactSet. Stephen Hansen, Associate Editor solanezumab (LY2062430) Eli...
BioCentury | Dec 6, 2019
Clinical News

Biogen Alzheimer’s data won’t sway believers or doubters either way

...really works.” Fillit referenced the post hoc analysis of the failed Phase III results for solanezumab...
...That trial failed in 2017 (see “ Not Dead Yet ”). “This reminds me of solanezumab,”...
BioCentury | Oct 26, 2019
Product Development

If approved, aducanumab will still have hills to climb

...DIAN-TU trials. The studies, which are being conducted in pre-symptomatic patients, are testing anti-amyloid antibodies solanezumab...
BioCentury | May 4, 2019
Product Development

How the amyloid hypothesis holds its grip

...enroll patients with mutations or risk factors for AD. Three of the five compounds -- solanezumab...
...Early AD 1,566 1.5 years March 2024 Prevent Symptom Onset Eli Lilly and Co. (NYSE:LLY) Solanezumab...
...FTDP-17) - Microtubule-associated protein τ Selina Koch, Senior Editor aducanumab (BIIB037) Amilomotide (CAD106) CNP520 crenezumab (MABT5102A, RG7412, Anti-Abeta) gantenerumab (R1450, RG1450) LY3002813 solanezumab (LY2062430) AC...
BioCentury | May 4, 2019
Product Development

Amyloid: how did we get here and what can we learn?

...weeks Missed Missed (n=47) PET Terminated after Study 301 failure Eli Lilly and Co. (NYSE:LLY) Solanezumab...
...up to poor CNS penetration, such as the three failed EXPEDITION trials of anti-amyloid mAb solanezumab...
...MAPT; FTDP-17) - Microtubule-associated protein τ Selina Koch, Senior Editor aducanumab (BIIB037) crenezumab (MABT5102A, RG7412, Anti-Abeta) gantenerumab (R1450, RG1450) solanezumab (LY2062430) Biogen...
BioCentury | Mar 23, 2019
Product Development

Baby steps beyond beta amyloid

...results on dose-response for cognition 11/23/16 - LLY: Eli Lilly and Co. (NYSE:LLY) reported that solanezumab...
BioCentury | Mar 22, 2019
Finance

Biogen's lead balloon

...results on dose-response for cognition 11/23/16 - LLY: Eli Lilly and Co. (NYSE:LLY) reported that solanezumab...
BioCentury | Mar 21, 2019
Clinical News

Biogen, Eisai discontinuing aducanumab studies in AD

...Roche (SIX:ROG; OTCQX:RHHBY) discontinued two Phase III trials of crenezumab to treat early AD, while solanezumab...
Items per page:
1 - 10 of 83